Abivax : ABX464 confirme son fort potentiel en RCH et l’intérêt spéculatif d’Abivax
>ABX464 passe avec succès sa phase 2b - Abivax a présenté hier après clôture les résultats topline de la phase 2b d’ABX464 dans la rectocolite hémorragique. Ceux-ci ressortent statistiquement significatifs sur le critère principal : réduction du Mayo score modifié après 8 semaine d’induction et ce à chacune des 3 doses testées. Ces résultats prometteurs, avec notamment une efficacité jugée impressionnante chez les patients ayant échoué sous biologiques ou JAK inhibito...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.